NewLink Genetics Signs $1 Billion Deal with Genentech for Cancer Drug Research and Development

Palo Alto – October 22, 2014 – Cooley advised NewLink Genetics Corporation in its negotiations with Genentech that resulted in an exclusive worldwide license agreement for the development of NLG919, NewLink's cancer immunotherapy. The agreement also calls for NewLink and Genentech to engage in a research collaboration for the discovery of next generation IDO/TDO compounds, which represent potential breakthrough approaches to cancer therapy.

NewLink is a biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutics to improve treatment options for patients with cancer. Immunotherapies are a class of drugs designed to help the body's own immune system fend off disease.

Under the terms of the agreement, Genentech will make a $150 million upfront payment to NewLink. NewLink is also eligible to receive in excess of $1 billion in milestone payments based on achievement of certain predetermined milestones. The agreement also provides for the payment to NewLink of escalating double-digit royalties on potential commercial sales of multiple products by Genentech.

The Cooley life sciences partnering team that advised NewLink included partners Marya Postner and Robert Jones, and associates Tracy Harrison and Rena Kaminsky. Critical support for the transaction was provided by corporate partner James Linfield; antitrust partner Francis Fryscak; and life sciences regulatory partner Natasha Leskovsek. 

View the company press release here.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has 800 lawyers across 11 offices in the United States and China.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.